AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46,483,529 | -37.8% | 4,512,964 | -0.5% | 0.34% | -8.8% |
| Q2 2023 | $74,735,498 | +78.4% | 4,534,921 | -0.8% | 0.38% | +38.6% |
| Q1 2023 | $41,884,008 | +108.0% | 4,572,490 | +62.6% | 0.27% | +68.9% |
| Q4 2022 | $20,137,428 | +42.9% | 2,812,490 | 0.0% | 0.16% | +78.9% |
| Q3 2022 | $14,091,000 | +105.3% | 2,812,490 | 0.0% | 0.09% | +125.0% |
| Q2 2022 | $6,862,000 | -68.6% | 2,812,490 | -12.1% | 0.04% | -59.6% |
| Q1 2022 | $21,850,000 | -3.2% | 3,199,152 | +14.5% | 0.10% | +16.5% |
| Q4 2021 | $22,581,000 | -17.6% | 2,794,673 | 0.0% | 0.08% | -24.1% |
| Q3 2021 | $27,388,000 | +45.6% | 2,794,673 | 0.0% | 0.11% | +36.6% |
| Q2 2021 | $18,808,000 | -25.6% | 2,794,673 | 0.0% | 0.08% | -47.4% |
| Q1 2021 | $25,264,000 | +24.9% | 2,794,673 | -7.7% | 0.16% | +26.8% |
| Q4 2020 | $20,225,000 | – | 3,027,705 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,409,289 | $24,815,676 | 12.25% |
| Knoll Capital Management, LLC | 600,000 | $6,180,000 | 6.42% |
| Vivo Capital, LLC | 4,096,428 | $42,193,208 | 4.62% |
| GENDELL JEFFREY L | 5,615,350 | $57,838,105 | 3.29% |
| Tri Locum Partners LP | 983,602 | $10,131,101 | 3.24% |
| Samsara BioCapital, LLC | 967,527 | $9,965,528 | 3.05% |
| MPM BioImpact LLC | 664,224 | $6,841,507 | 1.83% |
| COWEN AND COMPANY, LLC | 2,338,302 | $24,084,510 | 1.68% |
| RTW INVESTMENTS, LP | 7,136,415 | $73,505,075 | 1.55% |
| TANG CAPITAL MANAGEMENT LLC | 1,000,000 | $10,300,000 | 1.45% |